Bengü Dursun
A5040417559- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Male Breast Health Studies
- Lung Cancer Research Studies
- Polyomavirus and related diseases
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Nanoplatforms for cancer theranostics
- Sarcoma Diagnosis and Treatment
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research
- Tumors and Oncological Cases
- Cancer Cells and Metastasis
- Viral-associated cancers and disorders
- Bone Tumor Diagnosis and Treatments
- Neuroblastoma Research and Treatments
- Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
Ankara University
2022-2025
This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines treatment in patients with metastatic neuroendocrine tumors (NETs).
The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to HER2-positive group indicates this has a distinct histology HER2-0 group. effectiveness of cyclin-dependent kinase 4/6 inhibitors, which are standard first-line treatment for hormone receptor-positive, HER2-negative advanced cancer, newly defined histological subgroup remains topic debate. In our...
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. aim study was to evaluate prognostic status early triple negative breast cancer(TNBC). In TNBC patients who were treated with chemotherapy (NAC) and surgery analyzed retrospectively. primary analyze status(Her2-0 Her2-low) on pathological complete response (pCR). secondary objectives disease free survival (DFS) overall (OS). 620 female cancer evaluated. 427 (68.9%) had Her2-0 193(31.1%) her2-low...
<b>Background:</b> Treatment options for metastatic unresectable osteosarcoma are limited, and there is no standard approach after the failure of first-line chemotherapy. Conventional chemotherapy in second subsequent lines typically yield a median progression-free survival (PFS) less than 4 months, with objective response rates ranging from 3 to 29%. The activity anti-vascular endothelial growth factor receptor multi-tyrosine kinase inhibitors (TKIs) bone sarcomas has been...
Background: Pancreatic cancer is among the cancers with worst prognosis and therefore adjuvant treatment very important for reducing mortality.The aim of this study to compare gold standard mFolfirinox regimen other regimens in pancreatic real-world practice.Materials methods: Patients who underwent resection received at least one dose chemotherapy were included as two groups, Others (at a ratio 1:2).The primary endpoint was disease-free survival (DFS).Secondary endpoints determined overall...
The advances in immune checkpoint inhibitors (ICIs) were relatively slow rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and combination ICIs with chemotherapy (CT) patients advanced